Summary Tumour tissue oxygenation has been measured in man during carbogen breathing (95% 02, 5% C02) using a commercially available polarographic electrode system (Eppendorf P02 histograph). At least 200 tumour measurements in each of 17 patients with accessible tumours were taken before, and subsequently continuously after the commencement of carbogen breathing for periods of 10 to 30 min. In 12 out of 17 patients studied there was a significant increase in median tumour P02 during the first 10 min of carbogen breathing (range 9 to 1800%). There was an initial rapid increase in tumour P02 which was maintained until 8 to 12 min, but then decreased throughout the subsequent treatment period. Although there was a reduction in the proportion of point measurements < IO mmHg in 11 out of 13 patients, during carbogen breathing, measured points of < 2.5 mmHg were only eliminated in three out of 11 tumours. The time course has implications for the planning of clinical trials utilising radiotherapy with carbogen breathing.
The presence of hypoxic cells within tumours is widely regarded as one major determinant of treatment failure in patients following radical radiotherapy (Thomlinson & Gray, 1955) . One approach to overcome tumour hypoxia, which has been explored in the past is the use of carbogen breathing (95%, 02, 5% C02), prior to and during radiation treatment Keresteci & Rider, 1973; Rubin et al., 1979) . Interest in this technique has been revived, in association with modifiers of blood flow such as nicotinamide, following encouraging experimental results in mice (Rojas, 1991) .
There is substantial indirect evidence for hypoxia in human tumours, including by histopathological observations (Thomlinson & Gray, 1955) , positron emission tomography (Beaney et al., 1984) , radiolabelled radiosensitising adducts (Urtasun et al., 1986) , and flow cytometric evaluation using fluorescence immunodetection (Hodgkiss et al., 1991) . However, because of a lack of suitable equipment, few direct measurements of tumour tissue oxygenation have been performed in patients until recently. We have used the polarographic electrode system (Eppendorf P02 histograph) to measure directly both normal and tumour tissue P02. This system uses reliable, mechanically and electrically stable 350 ltm electrodes, that move in programmable steps. A series of 200 measurements can usually be completed in 10 min, and this method has provided further information on patterns of normal and tumour tissue oxygenation (Kallinowski et al., 1990; Vaupel et al., 1991; Hockel et al., 1991) .
Clinical experience with carbogen breathing has been disappointing to date. Studies in patients treated with radical radiotherapy for bladder cancer (Keresteci & Rider, 1973) , and postoperative pelvic radiotherapy for stage 1-3 ovarian cancer in Toronto in the 1970's failed to demonstrate a therapeutic benefit for carbogen breathing or normobaric oxygen. Similarly, a large trial in advanced head and neck cancer performed by the Radiation Therapy Oncology Group (Rubin et al., 1979) , showed no significant improvement in loco-regional control or overall survival by breathing carbogen. In each case patients breathed carbogen for up to 2 h prior to treatment. However, in isotransplanted syngenic mammary tumours in C3H mice, carbogen inhalation for 0.5 min immediately before radiotherapy increased the rate of cure (Inch et al., 1970) (1984) , construction of which has been described elsewhere . Before series of measurements the system was calibrated using sterile buffered 0.9% sodium chloride pH 7.8 equilibrated alternately with air and 100% nitrogen at room temperature for at least 30 min. To eliminate inter-observer variation all measurements were performed by one individual. Following injection of local anaesthetic (without vasoconstrictor), the 350 Am electrode was inserted through a 22G intravenous cannula (Venflon, Viggo UK) to protect the probe from unnecessary trauma in puncturing the skin. The electrode was allowed to stabilise in normal subcutaneous tissue and then advanced into tumour. The probe advanced stepwise in programmable steps usually of 0.7 mm forwards, followed immediately by a 0.3 mm backward motion in order to minimise tissue compression artefacts. The probe was positioned initially under direct visual control and then at least 200 different measurements were taken in 7-10 paths, over approximately O min. The probe entered the tumour at an angle whereby the maximum number of readings could be taken reliably without patient discomfort through each study.
To ensure that the same region of the tumour was sampled prior to and during carbogen therapy, whilst avoiding artefactual results due to prior tissue trauma from the electrode, the tumour tissue sampled was changed after completion each preset electrode path by rotating the probe 90 degrees within its holder, and/or changing the angle of the electrode path by 5-10 degrees. The maximum depth of tumour sampled was 4 cm. Each individual measurement was displayed as it was collected, and subsequently presented as frequency histograms of tissue P02. Measurements obtained in preliminary studies in untreated patients were considered reproducable and reliable enough for us to examine the time course of events during carbogen breathing. In addition Hockel et al. (1991) found that there was no significant difference in the number of values obtained in the lowest P02 class (0-2.5 mmHg) when a few electrode paths were compared with multiple paths. All comparisons between different series of measurements were performed by non-parametric analysis of the central tendencies of change using the MannWhitney 'U-test'.
The observed values represent point measurements within tumour which may be viable or necrotic, and close to or far from any blood vessel. We therefore present the data as median values and as percentage change from pre-carbogen breathing. Interpretation in terms of radiobiological hypoxia is also difficult and we have defined readings < 10 mmHg as being indicative of the likelihood of zones of radiobiological hypoxia (Hall, 1987) , with readings < 2.5 mmHg being defined as less than half maximum radiosensitivity . tological type. These findings confirm previously reported data using this measuring system (Kallinowski et al., 1990 (Table I) . Radiobiologically hypoxic values (< 10 mmHg) were recorded in 13 out of the 17 tumours studied. In 11 out of these 13 patients there was a decrease in the percentage of values < 10 mmHg during carbogen breathing, however the magnitude of that reduction was not consistent. Tumour P02 measurements prior to breathing carbogen Measurements in normal subcutaneous tissue and muscle have been performed in 20 patients and reported elsewhere (Bleehen et al., 1991) . Median P02 in these tissues was 31 mmHg. Values obtained ranged from 0 to 80 mmHg, and tended towards a pattern of a normal distribution.
A series of 200 measurements in each tumour was performed prior to carbogen breathing. Compared with normal tissue, tumour P02 histograms in general demonstrate a shift of the distribution to the left. This relative lack of high values and a preponderance of lower P02 values suggests the presence of tissue hypoxia, rather than high oxygen respiration rates (Figure la) . Table I shows the histological type, site, size, and median P02 of the tumours examined. There was marked intertumour variability with well oxygenated and poorly oxygenated tumours observed, e.g. median P02 in the five breast tumours studied ranged from 5 to 50 mmHg. No association was observed between median tissue oxygenation and tumour volume, haemoglobin concentration, or histological grade of tumour (data not shown) in any his- Figure 2 illustrates the response in three patients in whom there were significant increases in median P02 during the first 10 min of carbogen breathing. Maximum median tumour P02 was observed at between 8 and 12 min. In each patient demonstrated there was a subsequent decline in median P02 between 12 and 18 min. In two out of the three patients shown this decline in tumour P02 was statistically significant (MannWhitney U-test, P < 0.0271). Figure 3 shows a plot of individual point measurements in a patient with multiple untreated subcutaneous nodules due to metastatic melanoma with apparent sensitisation by carbogen breathing. In this patient hypoxic values < 2.5 mmHg were abolished, and values < 10 mmHg were reduced from 23 to 9%. Median P02 rose rapidly initially, but declined to a small increase above air breathing levels at 18 min which remained a significant increase when values obtained prior to breathing carbogen were compared to those obtained between 18 and 20 min (P = 0.0439). Between 11 and 13 min median P02 was 67 mmHg and this declined significantly to 12 mmHg between 16 and 19 min (P = 0.0325). In contrast Figure 4 shows the individual point measurements obtained prior to and during carbogen breathing in a patient with extensive small cell lung cancer with multiple subcutaneous nodules, who had received no prior anti-cancer therapy. In this patient carbogen breathing had no apparent effect on either median P02, and neither was there sensitisation of hypoxic values. Time from start of carbogen breathing (min) Figure 4 The effects of carbogen breathing on a subcutaneous deposit of untreated extensive small cell lung cancer showing no effect on tumour P02 or hypoxic values. 0, individual measurement.
, median tumour PO2 pooled from 30 to 50 individual measurements.
We have demonstrated that the Eppendorf P02 histograph electrode system is well tolerated by patients, reliable, and has shown consistent changes in tumour P02 during carbogen breathing. Carbogen breathing significantly increased median tumour P02 in 12 out of the 17 patients studied. The increase in tumour P02 however was extremely variable. This confirms previous observations by Evans and Naylor (1963) , who showed that breathing 100% oxygen at one atmosphere produced an increase in tumour oxygen tension in 20 out of 22 single microelectrode measurements in five patients. Kolstad (1968) used single microelectrode measurements in cervical cancer and showed that there was a rapid increase in tumour P02 after a latency period of 20-30 s following the commencement of patients breathing atmospheric oxygen. In some tumours studied, particularly with more advanced disease, there was no apparent increase in tumour oxygenation during oxygen breathing, and the rise in tumour P02 was slower than that of normal tissue. We have demonstrated that tumour P02 does rise rapidly initially, and continues to increase up to 8-12 min after the commencement of carbogen breathing. This has been attributed to the 5% CO2 in carbogen causing vasodilatation, tachycardia, increased respiratory drive, and thus improved tissue oxygen delivery (DuSault, 1963) . Consistent with this hypothesis we have observed a 55% increase in red blood cell flux measured by an implantable probe, using laser doppler flowmetry, in a patient with locally advanced carcinoma of breast in the first 5 min of carbogen breathing (unpublished data). However when carbogen breathing was continued up to 18 min there was a reduction in median tumour P02.
Normobaric oxygen was breathed for periods up to 2 h in patients with transitional cell carcinoma of the bladder prior to radical radiotherapy, with no improvement in survival (Keresteci & Rider, 1973) . Similarly, there was no difference in the relapse free survival in patients with post-operative stage 1-3 ovarian cancer treated with pelvic irradiation, who breathed carbogen immediately before and during treatment . A large trial of carbogen breathing was undertaken by the RTOG in 254 patients treated with radical radiotherapy for advanced carcinomas of the head and neck (Rubin et al., 1979) . Patients breathed 100% 02 for 10 to 20 min, and then carbogen for periods of 15-30 min prior to, and during treatrnent. This failed to show any improvement in either overall survival, or loco-regional control, however, there was no increase in toxicity.
One clinical trial has shown a small therapeutic advantage to breathing atmospheric oxygen 5-10 min prior to and during radical external beam radiotherapy for stage II carcinoma of cervix (Bergsjo & Kolstad, 1968; 33 .1% local failure in controls compared to 30.1% in oxygen breathing). Interestingly, there were only 22.4% local failures in that group of patients that breathed atmospheric oxygen for 15 min in each hour during a 120 h radium insertion as well as during external beam therapy, although the difference was not statistically significant.
The pre-irradiation breathing time has been shown to be of considerable importance in the radiosensitisation by carbogen breathing of tumours in mice (Inch et al., 1970) . Further studies in mice have confirmed a time dependence of therapeutic gain with carbogen breathing, and it has been postulated that this may be due to variations in tumour blood flow, rather than changes in oxygen dissociation (Siemann et al., 1977) . Previous clinical trials may therefore have failed to show an improvement in tumour control with carbogen breathing on account of suboptimal timing. Our data suggest that the optimal increase in tumour P02 by carbogen occurs in the first 12 min, and therefore carbogen breathing in any future clinical trials should commence immediately before the first radiation field is treated, without any preliminary 'soaking' period. Many patients found breathing carbogen through our closed system difficult and claustrophobic. The maximum tolerated time of carbogen breathing was 30min, although ten of our patients, usually with advanced and metastatic disease could only manage the mask inside their mouths for periods of 10-20 min. This system is therefore unlikely to be suitable for the use of carbogen breathing in routine clinical practice, and a more acceptable system needs to be developed.
Pooled data from experiments performed in yeast, bacteria and mammalian cells suggest that oxygen concentrations of 0.5% or approximately 3 mmHg corresponds to less than half maximum radiosensitivity (Hall, 1987) , and values < 10 mmHg correspond to reduced radiosensitivity. Whilst the proportion of hypoxic values < 10 mmHg (identified in 13 out of 17 tumours studied) fell in 11 of these tumours studied during the first 10 min of carbogen breathing, values < 2.5 mmHg (where present in initial measurements) were only abolished in three out of 11 tumours. These findings are consistent with experimental findings and mathematical modelling of carbogen breathing in DS-carcinosarcoma (Vaupel, 1977) , which predicted that owing to the limited diffusion of oxygen eradication of hypoxic areas could only occur at the arterial end of a capillary supply system. This electrode technique however cannot differentiate between low P02 values in necrotic non-viable tissue, and more importantly low P02 values due to hypoxic, yet clonogenically viable malignant cells. Neither can it differentiate between values obtained from viable tumour cells, and supporting non-malignant stroma, or distinguish between oxygen-deficient areas and areas with high consumption rates creating steep P02 gradients, such that low P02 values are apparently measured in the absence of metabolic hypoxia. This issue is in part addressed by the large number of individual readings (200-430) taken during carbogen breathing in this study. However, our results show an incomplete reduction of measured points < 10 mmHg in tumour at presumed radiobiologically hypoxic P02 levels during carbogen breathing. This suggests that carbogen breathing alone, even when given with optimal timing relative to X-radiation is unlikely to produce a marked therapeutic gain. Further studies with additional agents to modify tumour perfusion are needed and are in progress.
